(Q40406803)

20 September 2017

title

An introduction to multiplicity issues in clinical trials: the what, why, when and how. (English)

1 reference

20 September 2017

8

Lehana Thabane

1 reference

20 September 2017

Philip James Devereaux

7

object named as

Philip J Devereaux

1 reference

20 September 2017

5

Deborah J Cook

1 reference

20 September 2017

Guowei Li

1

1 reference

20 September 2017

Monica Taljaard

2

1 reference

20 September 2017

Edwin R Van den Heuvel

3

1 reference

20 September 2017

Mitchell Ah Levine

4

1 reference

20 September 2017

George A Wells

6

1 reference

20 September 2017

publication date

26 December 2016

1 reference

International Journal of Epidemiology

20 September 2017

published in

1 reference

20 September 2017

volume

46

1 reference

20 September 2017

issue

2

1 reference

20 September 2017

page(s)

746-755

1 reference

Practical guidelines for multiplicity adjustment in clinical trials.

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

Multiplicity in randomised trials I: endpoints and treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

Reporting of primary analyses and multiplicity adjustment in recent analgesic clinical trials: ACTTION systematic review and recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

Correcting for multiple-testing in multi-arm trials: is it necessary and is it done?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

Adjusting for multiple testing--when and how?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

The cost of large numbers of hypothesis tests on power, effect size and sample size.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

More multiarm randomised trials of superiority are needed

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

Reporting of analyses from randomized controlled trials with multiple arms: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

Multi-arm clinical trials of new agents: some design considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

Do multiple outcome measures require p-value adjustment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

Clinical trials with multiple outcomes: a statistical perspective on their design, analysis, and interpretation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

Analyzing multiple endpoints in clinical trials of pain treatments: IMMPACT recommendations. Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

Composite outcomes in randomized clinical trials: arguments for and against

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

Multiplicity in randomised trials II: subgroup and interim analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

Designs for group sequential tests.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

Interim analyses and sequential designs in phase III studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

Stopping rules for phase II studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

Challenging Issues in Clinical Trial Design: Part 4 of a 4-Part Series on Statistics for Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

A Multiple Testing Procedure for Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

Approximately optimal one-parameter boundaries for group sequential trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

Discrete sequential boundaries for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

Frequentist evaluation of group sequential clinical trial designs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

Repeated measurements and multiple comparisons in cardiovascular research

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

The analysis of repeated measures designs: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

Statistical Controversies in Reporting of Clinical Trials: Part 2 of a 4-Part Series on Statistics for Clinical Trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

The problem of subgroup analyses: an example from a trial on ruptured intracranial aneurysms

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

A tutorial on sensitivity analyses in clinical trials: the what, why, when and how.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

Use of an embedded, micro-randomised trial to investigate non-compliance in telehealth interventions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

Dalteparin versus Unfractionated Heparin in Critically Ill Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

Risk factors for and prediction of mortality in critically ill medical-surgical patients receiving heparin thromboprophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

Co-enrollment of critically ill patients into multiple studies: patterns, predictors and consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

PROphylaxis for ThromboEmbolism in Critical Care Trial protocol and analysis plan

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

What's wrong with Bonferroni adjustments

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

A sharper Bonferroni procedure for multiple tests of significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

Advanced multiplicity adjustment methods in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

Multiple Hypothesis Testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

Multiple Comparisons Procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYW320

21 January 2018

Identifiers

DOI

10.1093/IJE/DYW320

1 reference

20 September 2017

1 reference